Fuchs' endothelial corneal dystrophy: pathology and treatment outcome

Nielsen, Esben

doi:10.1111/aos.13311

Acta Ophthalmologica

2016

DOI: 10.1111/aos.13311

|View full text |Cite

Fuchs' endothelial corneal dystrophy: pathology and treatment outcome

Esben Nielsen

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Descemet membrane endothelial keratoplasty combined with presbyopia‐correcting and toric intraocular lenses – a narrative review

Rodríguez-Calvo-de-Mora,

Rocha-de-Lossada,

Romano

et al. 2023

BMC Ophthalmol

View full text Add to dashboard Cite

Fuchs endothelial corneal dystrophy (FECD) is the leading indication for EK and may coexist with cataract and presbyopia. Notably, the outcomes of phacoemulsification in FECD patients are not as favorable as those in eyes without this condition. Historically, only monofocal intraocular lenses (IOLs) were recommended for these patients. However, recent reports have described the implantation of Premium-IOLs (such as Multifocal IOLs, Enhanced Depth of Focus IOLs, and Toric IOLs) in FECD eyes undergoing cataract surgery and Descemet membrane endothelial keratoplasty (DMEK). While the results are encouraging, they are not as optimal as those from unoperated eyes, especially when comparing simultaneous procedures to sequential ones. It’s advised to perform the DMEK first to improve the accuracy of IOL calculations. Still, even successfully operated eyes may experience secondary graft failure or graft rejection after DMEK. The success rate of a secondary DMEK is typically lower than that of the initial procedure. Furthermore, if the postoperative thickness after DMEK is less than anticipated, laser enhancements might not be an option. There’s a pressing need for more controlled and randomized clinical trials to ascertain the safety and effectiveness of Premium-IOLs for FECD eyes. This narrative review aims to collate evidence on the use of Premium IOL technologies in eyes receiving EK and to underscore key points for surgeons performing EK combined with cataract surgery.

show abstract

Descemet membrane endothelial keratoplasty combined with presbyopia‐correcting and toric intraocular lenses – a narrative review

Rodríguez-Calvo-de-Mora,

Rocha-de-Lossada,

Romano

et al. 2023

BMC Ophthalmol

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Fuchs' endothelial corneal dystrophy: pathology and treatment outcome

Cited by 1 publication

References 104 publications

Descemet membrane endothelial keratoplasty combined with presbyopia‐correcting and toric intraocular lenses – a narrative review

Descemet membrane endothelial keratoplasty combined with presbyopia‐correcting and toric intraocular lenses – a narrative review

Contact Info

Product

Resources

About